Leukemia (AML): Ivosidenib Expanded Access Program in Relapsed/Refractory AML With
an IDH1 Mutation
There is no research question. This is an expanded access program.
Basic Study Information
Purpose:Location: Cancer Center
This is an expanded access program. The program is sponsored by the pharmaceutical
company named Agios Pharmaceuticals, Inc. (the "Sponsor"). The purpose of this EAP
is to provide access to ivosidenib to qualifying patients during the period of time
prior to the potential approval and commercial availability of ivosidenib.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03245424?term=AG120-C-010&rank=1
Study Reference #: ELEU18003
Lead Researcher (Principal Investigator)
Lead Researcher: Jason Mendler
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Learn More About These Conditions
More information about Leukemia, Myeloid, Acute
Trial Not Found
The study you are looking for is not active at this time.
Return to Search